Compare · NTR vs NXTS
NTR vs NXTS
Side-by-side comparison of Nutrien Ltd. (NTR) and Nexentis Technologies Inc. (NXTS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NTR and NXTS operate in Agricultural Chemicals (Industrials), so they compete in similar markets.
- NTR is the larger of the two at $33.53B, about 33040.6x NXTS ($1.0M).
- Over the past year, NTR is up 23.8% and NXTS is down 97.6% - NTR leads by 121.3 points.
- NXTS has been more active in the news (4 items in the past 4 weeks vs 3 for NTR).
- NTR has more recent analyst coverage (25 ratings vs 0 for NXTS).
PerformanceNTR+23.76%NXTS-97.55%
2025-10-20+0.00%2026-10-16
- Company
- Nutrien Ltd.
- Nexentis Technologies Inc.
- Price
- $71.28+2.41%
- $0.61-2.56%
- Market cap
- $33.53B
- $1.0M
- 1M return
- -9.71%
- -48.05%
- 1Y return
- +23.76%
- -97.55%
- Industry
- Agricultural Chemicals
- Agricultural Chemicals
- Exchange
- NYSE
- NASDAQ
- IPO
- 2004
- News (4w)
- 3
- 4
- Recent ratings
- 25
- 0
NTR
Nutrien Ltd.
Nutrien Ltd. provides crop inputs, services, and solutions. The company offers potash, nitrogen, phosphate, and sulfate products; and financial solutions. It also distributes crop nutrients, crop protection products, seeds, and merchandise products through approximately 2,000 retail locations in the United States, Canada, South America, and Australia. The company was incorporated in 2017 and is headquartered in Saskatoon, Canada.
Latest NTR
- Nutrien Announces Release Dates for Third Quarter 2026 Results and Conference Call
- SEC Form 6-K filed by Nutrien Ltd.
- Nutrien Provides Update on Trinidad Nitrogen Operations
- Nutrien to Host Investor Day on November 30
- KeyBanc Capital Markets initiated coverage on Nutrien
- Nutrien downgraded by National Bank Financial with a new price target
- SEC Form SD filed by Nutrien Ltd.
- SEC Form 6-K filed by Nutrien Ltd.
- SEC Form 6-K filed by Nutrien Ltd.
- Nutrien Declares Quarterly Dividend of US$0.55 per Share
Latest NXTS
- Nexentis: MitoCareX Bio Expands Computational Biology Capabilities to Advance Disease-Pathway Analysis
- Nexentis: MitoCareX Bio Deploys its Computational Drug Discovery Infrastructure on Google Cloud
- SEC Form 8-K filed by Nexentis Technologies Inc.
- SEC Form PRE 14A filed by Nexentis Technologies Inc.
- Nexentis: MitoCareX Strengthens Its Computational Drug Discovery Capabilities with Appointment of Prof. Dan T. Major to Scientific Advisory Board
- Nexentis: MitoCareX Evaluates Expanded Protein Capabilities to Enhance Flexibility and Support Future Drug Discovery
- Nexentis Technologies Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- SEC Form 10-Q filed by Nexentis Technologies Inc.
- Nexentis Technologies Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits
- Nexentis Technologies Subsidiary MitoCareX Bio Selects Transport Protein Candidate for Drug Discovery Campaign